Tesamorelin / Ipamorelin / MGF

Tesamorelin / Ipamorelin / Mechano Growth Factor Blend

A triple-action GH blend combining GHRH stimulation, GHRP pulsatility, and local muscle growth factor for comprehensive GH optimization.

100% 50% · t½ Time → Serum level
Molecular Weight Not specified
Half-Life Varies
Typical Dose 0.8 mg to 2.4 mg
Cycle Length 8–16 weeks

Description

This pre-formulated blend combines three complementary peptides: Tesamorelin (GHRH analog for sustained GH release), Ipamorelin (selective GHRP for pulsatile GH), and MGF (Mechano Growth Factor for local muscle repair and growth). Together they provide synergistic GH optimization with added anabolic support.

Key Characteristics

Molecular Formula

Molecular Weight

Half-Life

Administration Routes

Subcutaneous injection

Typical Dose

0.8 mg to 2.4 mg

Frequency

Daily or as directed

Investigated Benefits

* Benefits based on preclinical/animal research unless otherwise noted.

Mechanism of Action

“A triple-action GH blend combining GHRH stimulation, GHRP pulsatility, and local muscle growth factor for comprehensive GH optimization.”

Tesamorelin stimulates pituitary GH synthesis via GHRH receptors. Ipamorelin amplifies GH pulses via GHS-R1a. MGF (a splice variant of IGF-1) activates satellite cells for local muscle repair and hypertrophy through IGF-1 receptor signaling.

Administration Routes

Subcutaneous injection

Key Characteristics

Typical Dose

0.8 mg to 2.4 mg

Frequency

Daily or as directed

Cycle Length

8–16 weeks

Administration

Subcutaneous injection

Protocol Notes

Administer on empty stomach for best GH response. Bedtime dosing recommended. MGF component provides additional anabolic support for muscle recovery.

Reconstitution Guide

Add 3 mL bacteriostatic water to blend vial. Follow prescriber instructions for exact dosing.

Storage Information

Lyophilized: refrigerate. Reconstituted: refrigerate and use within 30 days.

Quality & Sourcing Standards

When sourcing Tesamorelin / Ipamorelin / MGF for research purposes, the following quality benchmarks should be verified before use.

Purity:

>98% (verified by HPLC)

Certificate of Analysis (COA):

Must be provided by supplier

Endotoxin Testing:

<0.1 EU/mg (prevents bacterial contamination)

GMP Compliance:

Manufactured in cGMP-certified facility

Third-Party Testing:

Independent lab verification preferred

Storage Information

Lyophilized: refrigerate. Reconstituted: refrigerate and use within 30 days.

FDA Disclaimer

The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.

Research Highlights

1

Tesamorelin FDA-approved for HIV-associated lipodystrophy

2

Ipamorelin demonstrated selective GH release without cortisol elevation

3

MGF shown to activate muscle satellite cells in multiple studies

Evidence Level

Multiple animal studies and/or early human trials. Reasonable confidence in mechanism, but human data is limited.

Compatible Peptides

Peptides commonly used alongside Tesamorelin / Ipamorelin / MGF for synergistic effects.

BPC-157

A synthetic pentadecapeptide derived from gastric juice with extraordinary tissue healing properties across multiple organ systems.

TB-500

A synthetic analog of Thymosin Beta-4 that promotes systemic healing through actin regulation and angiogenesis.

Quick Reference

Category

Blends & Combos

Status

Research Only

Dose

0.8 mg to 2.4 mg

Frequency

Daily

Cycle

8–16 weeks